Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) launched two patient-centric initiatives for World Glaucoma Week, aimed at raising awareness of glaucoma. The initiatives include a global education campaign called “Making an iMPACT: Glaucoma Perspectives” featuring interviews with leading physicians and a glaucoma patient. Additionally, Glaukos will collaborate with U.S. eye care institutions to provide free glaucoma screenings. These efforts underline Glaukos' commitment to improving glaucoma treatment and patient education across the globe.
Glaukos Corporation (NYSE: GKOS) announced its management's virtual participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 3:10 p.m. EDT. This event will be available via live and archived webcast on Glaukos' Investors website. Glaukos specializes in medical technology and pharmaceuticals for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent series.
Glaukos Corporation (NYSE: GKOS) has appointed Denice Torres and Dr. Leana Wen as new members of its Board of Directors, increasing the board to nine members, eight of whom are independent. The addition aims to enhance the board's expertise as the company continues to expand its global presence in ophthalmic medical technologies. Torres, with over 25 years in healthcare management, previously held leadership roles at Johnson & Johnson, while Dr. Wen is known for her public health advocacy and emergency medicine expertise. Their insights are expected to benefit Glaukos' mission in treating chronic eye diseases.
Glaukos Corporation (GKOS) reported Q4 2020 net sales of $73.2 million, an increase from $65.8 million in Q4 2019. The gross margin stood at approximately 73%, down from 76% year-over-year. For 2020, overall net sales fell 5% to $225.0 million, with a net loss of $120.3 million or ($2.70) per diluted share. Despite losses, the company ended the year with $413.9 million in cash and investments. They forecast a 15%-20% increase in Q1 2021 net sales compared to the previous year.
Glaukos Corporation (NYSE: GKOS) announced positive results from its Phase 3 trial of iLink™ Epi-on therapy for treating keratoconus. The trial met its primary efficacy endpoint, showing a statistically significant improvement in maximum corneal curvature (Kmax) at 6 months. The treatment group exhibited a Kmax improvement of -1.0D (p = 0.0004), indicating the therapy's effectiveness. With 98% of placebo patients opting for Epi-on after the trial, safety was affirmed as 97% completed the study. Glaukos aims for FDA submission in 2022 and anticipates approval in 2023, capitalizing on this promising therapy.
Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, after market closure. A conference call to discuss these results will take place at 1:30 p.m. PST (4:30 p.m. EST) on the same day. Investors can access the live webcast through the company’s website. Glaukos specializes in innovative treatments for glaucoma and other ocular conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices such as the iStent® and iStent inject®.
Glaukos Corporation (GKOS) announced positive interim results from its 24-month Phase 2b trial of the iDose® TR implant for glaucoma treatment. The trial, involving 154 subjects, showed sustained reductions in intraocular pressure (IOP) with average decreases of 7.9 mmHg and 7.4 mmHg for fast- and slow-release arms, respectively, compared to 7.8 mmHg for the timolol control. The implant aims to offer a durable alternative to daily eye drops. Glaukos is focused on completing enrollment for the Phase 3 trials, targeting FDA approval for 2023.
Glaukos Corporation (NYSE: GKOS) announced preliminary, unaudited net sales for Q4 and the full year ending December 31, 2020. Q4 net sales are estimated at $73 million, with $58 million from Glaucoma and $15 million from Corneal Health. For the full year, net sales are projected at $225 million, driven by $179 million in Glaucoma and $46 million in Corneal Health. CEO Thomas Burns acknowledged the team's efforts amidst COVID-19 challenges and expressed confidence in the company's future, although caution remains due to ongoing uncertainties. Final results will be available in late February.
Glaukos Corporation (NYSE: GKOS) announced promising 12-month data from its U.S. Investigational Device Exemption pivotal trial for the iStent infinite Trabecular Micro-Bypass System, indicating significant effectiveness in lowering intraocular pressure (IOP) in patients with open-angle glaucoma. In the trial, 76% of participants experienced a 20% or greater reduction in mean IOP, with over 50% achieving a ≥30% reduction. The study reported a favorable safety profile, with no serious complications noted. Glaukos plans to submit for FDA approval of the device, aiming for a late 2021 target.
Glaukos Corporation (NYSE: GKOS) announced its management will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 11:00 a.m. PST. Investors can access a live and archived webcast on the company's website. Glaukos focuses on innovative therapies for glaucoma and other ophthalmic conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent® devices launched since 2012. The company's technology aims to transform glaucoma treatment and enhance corneal health through specialized pharmaceuticals and surgical therapies.